Carcinoembryonic Antigen Clearance Rate May Be a Prognostic Indicator for Metastatic Colorectal Cancer Patients Receiving Chemotherapy
Autor: | Jeng Kai Jiang, Shih Ching Chang, Shung Haur Yang, Chun Chi Lin, Sheng Chieh Huang, Jen Kou Lin, Tzu Chen Lin, Wei Shone Chen, Huann Sheng Wang |
---|---|
Rok vydání: | 2016 |
Předmět: |
Oncology
medicine.medical_specialty Chemotherapy biology business.industry Colorectal cancer medicine.medical_treatment Medical record medicine.disease Single Center digestive system diseases 03 medical and health sciences 0302 clinical medicine Carcinoembryonic antigen 030220 oncology & carcinogenesis Internal medicine biology.protein Medicine 030211 gastroenterology & hepatology Surgery Metastasectomy business neoplasms Clearance rate Tumor marker |
Zdroj: | International Surgery. 101:510-516 |
ISSN: | 2520-2456 0020-8868 |
Popis: | To figure out the relationship between the tumor marker clearance rate during the treatment period and the disease prognosis. Carcinoembryonic antigen (CEA) is a glycoprotein that has been widely used as a tumor marker in colorectal cancer for more than 30 years. This study evaluated the role of the CEA clearance rate during treatment and determined its relationship with chemotherapy regimens, increased metastasectomy rate, and overall survival. The medical records of 442 metastatic colorectal cancer patients whose primary tumors were treated with surgery followed by systemic therapy at a single center from 2000 to 2012 were reviewed. The CEA clearance rate was calculated as a change in CEA after 6 courses of therapy divided by the treatment period [(posttherapy CEA – pretherapy CEA)/days between therapy], and classified into 4 groups for further evaluation. The CEA clearance rate during treatment of stage IV colorectal cancer was significantly correlated with different chemotherapy regimens (P < 0.01); pretreatment CEA level (P < 0.01); tumor differentiation (P < 0.01); increased metastasectomy rate (P = .02); and overall survival (P < 0.01). The CEA clearance rate during systemic therapy could evaluate patient treatment responses more precisely than traditionally rising or falling CEA levels, and may predict disease prognosis. |
Databáze: | OpenAIRE |
Externí odkaz: |